Clinical trials incorporating biomarker-based stratification, such as GUIDE-IT (which assessed NT-proBNP-guided therapy) [98] and BIOSTAT-CHF (focusing on personalized treatment algorithms) [99], have demonstrated the clinical utility of integrating molecular diagnostics into heart failure (HF) management. The gene discussed is NPPB; the disease is hydrops fetalis.